Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Advaxis Inc (NASDAQ:ADXS)

3.79
Delayed Data
As of Oct 20
 0.00 / 0.00%
Today’s Change
3.76
Today|||52-Week Range
10.88
-47.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$155.6M

Company Description

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company's platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Advaxis was founded on June 5, 1987 and is headquartered in Princeton, NJ.

Contact Information

Advaxis, Inc.
305 College Road East
Princeton New Jersey 08540
P:(609) 452-9813
Investor Relations:

Employees

Shareholders

Mutual fund holders23.88%
Other institutional21.82%
Individual stakeholders15.96%

Top Executives

Anthony A. LombardoEVP, Chief Executive & Business Officer
Christopher M. DukeChief Operating Officer & Senior Vice President
Sara BonsteinChief Financial Officer & Senior Vice President
Robert G. PetitChief Scientific Officer & Executive VP
Mayo PujolsSenior Vice President-Technical Operations